Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Launched by MBRACE THERAPEUTICS ·

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment for people with advanced solid tumors, which are cancers that have spread and have not responded to standard treatments. The study is focused on several types of cancer, including prostate cancer that no longer responds to hormone therapy, breast cancer, colorectal cancer, and a type of lung cancer called non-small cell lung cancer. The main goals are to find the right dose of the new treatment, check if it is safe, and understand how the body processes the medicine.

The trial is open to adults between the ages of 65 and 74, regardless of gender, who have advanced cancer that has not improved with other treatments. Participants will receive the new treatment and be closely monitored to see how their bodies react and if the treatment helps control their cancer. Since this is an early-stage study, its main focus is on safety and dosing rather than effectiveness. It’s important to know that the trial has not started recruiting patients yet, but it will take place at multiple medical centers. If you or a loved one fits this description and are interested, talking to your doctor about this option might be helpful.

Gender

ALL

Eligibility criteria